Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma
Objective: Mepolizumab is indicated as an additional treatment of severe refractory eosinophilic asthma. The observed differences in population subgroups according to plasma eosinophil count, the existence of patients with high levels of immunoglobulin E who are candidates of omalizumab and mepolizu...
Збережено в:
Автори: | , , , , |
---|---|
Формат: | Книга |
Опубліковано: |
Elsevier,
2019-11-01T00:00:00Z.
|
Предмети: | |
Онлайн доступ: | Connect to this object online. |
Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
Інтернет
Connect to this object online.3rd Floor Main Library
Шифр: |
A1234.567 |
---|---|
Примірник 1 | Доступно |